VKTX Viking Therapeutics, Inc.

VKTX Viking Therapeutics, Inc.

Healthcare · Biotechnology

Market read

Scan convergence 1 scan as of 2026-08-17 1 neutral converging

POC $25.90 · VWAP $31.68 · +6.1% vs 12m avg buyer

pullback vol: compressedgaps: stablechurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

2 watchlists

VKTX Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist VKTX belongs to, members best 30-day change first — VKTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@peptide-economy
@biotech-capital-cycle

Desk commentary

Authored analysis and challenge notes tied to VKTX.

1

Next earnings VKTX reports in 71 days Oct 28

Against street estimates

How VKTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 9 quarters · newest report Jul 29 · projection Aug 17

Result
Jul 29 -1.21-1.10+8.8%Beat
Apr 29 -0.91-1.37-50.5%Miss
Feb 11 -0.90-1.38-53.1%Miss
Oct 22 '25 -0.67-0.81-20.1%Miss
Jul 23 '25 -0.44-0.58-31.6%Miss
Apr 23 '25 -0.31-0.41-31.7%Miss
Feb 5 '25 -0.27-0.32-19.7%Miss
Oct 23 '24 -0.24-0.22+8.1%Beat